Name (Synonyms) | Correlation | |
---|---|---|
drug408 | Biological Sample Collection Wiki | 0.71 |
drug2935 | Tocilizumab Injection Wiki | 0.50 |
drug412 | Biological sample collection Wiki | 0.50 |
Name (Synonyms) | Correlation |
---|
There are 2 clinical trials
In this study, defined cases of COVID-19 with mild, moderate or severe pneumonia will be treated with standard treatment regimens in combination with IV injection of Deferoxamine. Improvement in clinical, laboratory and radiological manifestations will be evaluated in treated patient compared to control group.
Description: All cause of death
Measure: Mortality rate Time: up to 20 daysDescription: Mild, Moderate or Severe
Measure: change in patients clinical manifestation Time: up to 20 daysDescription: days
Measure: Length of hospitalization Time: up to 20 daysAssessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, associated with standards treatments in COVID-19 (+) patients, Hospitalized In Intensive care in Tunisia. Multicentric, comparative, randomized study.
Description: Evaluate the mortality rate at 90 days. Evaluate the Intensive Care Unit (ICU) and Hospital Mortality rate at day 90 with date and cause of death (if applicable)
Measure: the mortality rate Time: 90 day